» Articles » PMID: 39781562

Tumor-Educated Platelets LncRNA-STARD4-AS1 and ELOA-AS1 As Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer

Overview
Publisher Dove Medical Press
Date 2025 Jan 9
PMID 39781562
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: (Tumor-educated platelets) TEPs have emerged as active players in all steps of tumorigenesis, confrontation of platelets with tumor cells via transfer of tumor-associated biomolecules and results in the sequestration of such biomolecules. The current study was aimed to examine whether TEPs lncRNA-STARD4-AS1 and ELOA-AS1 might be potential biomarkers for NSCLC.

Materials And Methods: TEPs were obtained by low-speed centrifugation. Quantitative real-time PCR was used to determine the expression level of TEPs-STARD4-AS1, ELOA-AS1 in the training cohort and the validation cohort. ROC curve was generated to evaluate their diagnostic value. Correlations between TEPs-STARD4-AS1, ELOA-AS1 and clinical parameters were further analyzed.

Results: Our results showed that the level of TEPs-STARD4-AS1 and ELOA-AS1 significantly upregulated in patients with NSCLC compared with healthy controls in the two cohorts. By ROC analysis, we found that TEPs-STARD4-AS1, ELOA-AS1 could offer valuable diagnostic performance for NSCLC patients (AUC = 0.800/0.774, and AUC = 0.754/0.718 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively). The combination of TEP-STARD4-AS1 and ELOA-AS1 improved the diagnostic efficiency of NSCLC. Clinicopathological analysis further revealed that TEPs-STARD4-AS1 level significantly correlated with tumor-node-metastasis (TNM) stage (p = 0.011), while TEPs-ELOA-AS1 expression significantly correlated with tumor-node-metastasis (TNM) stage and (p = 0.019) distant metastasis (p = 0.004).

Conclusion: Our data suggested that TEPs-STARD4-AS1 and ELOA-AS1 are promising non-invasive circulating diagnostic markers for NSCLC.

References
1.
Schmitz S, Grote P, Herrmann B . Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016; 73(13):2491-509. PMC: 4894931. DOI: 10.1007/s00018-016-2174-5. View

2.
Adjei A . Lung Cancer Worldwide. J Thorac Oncol. 2019; 14(6):956. DOI: 10.1016/j.jtho.2019.04.001. View

3.
Li J, Qiao Z, Li Y, Lu X, Shao T, Lv X . Bioinformatic analysis indicated that STARD4-AS1 might be a novel ferroptosis-related biomarker of oral squamous cell carcinoma. Heliyon. 2024; 10(12):e33193. PMC: 11250877. DOI: 10.1016/j.heliyon.2024.e33193. View

4.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A . Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472-84. DOI: 10.1038/nrclinonc.2013.110. View

5.
Walters S, Maringe C, Coleman M, Peake M, Butler J, Young N . Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013; 68(6):551-64. DOI: 10.1136/thoraxjnl-2012-202297. View